南模生物境外业务毛利率显著高于境内业务遭监管拷问

Core Insights - The company reported a total revenue of 381 million yuan for 2024, reflecting a year-on-year growth of 4.01%, with significant disparities in performance across different business segments [1] Group 1: Business Performance - The standardized model business generated revenue of 165 million yuan, up 16.58% year-on-year, driven by increased demand from research clients and improved cost control, with project numbers surging by 45% [2] - The model breeding business saw a revenue decline of 8.60% to 90.06 million yuan, primarily due to a significant drop in project prices, which fell from 20,600 yuan per project in 2023 to 14,400 yuan in 2024, overshadowing the growth in project numbers [2] - The overseas business revenue reached 53.06 million yuan, marking a 31.88% increase, with a gross margin of 70.9%, significantly outperforming the domestic business gross margin of 41.66% [2] Group 2: Customer Structure - Industrial clients contributed higher gross margins in standardized models and efficacy evaluation services, with average prices of 115,200 yuan per project compared to 22,900 yuan for research clients, and gross margins for industrial clients being 10-30 percentage points higher [3] Group 3: Inventory and Capacity Management - The company reduced its inventory balance to 12.67 million yuan, a decrease of 19.95% year-on-year, with an inventory turnover rate of 15 times, significantly higher than industry peers [4] - The company operates nine production bases with a total capacity of 140,000 cages, with a current capacity utilization rate of 80%, and plans to reduce reliance on leasing through a planned expansion project [4]